1. Araneta MRG, Wingard DL, Barrett-Connor E. Type 2 Diabetes and Metabolic Syndrome in Filipina-American Women A high-risk nonobese population. Diabetes Care. 2002. 25:494–499.
2. Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Bonner-Weir S, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab. 2003. 05. 88:2300–2308.
Article
3. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005. 366:1059–1062.
Article
4. Goodman E, Dolan LM, Morrison JA, Daniels SR. Factor analysis of clustered cardiovascular risks in adolescence: obesity is the predominant correlate of risk among youth. Circulation. 2005. 111:1970–1977.
Article
5. Park HS, Lee MS, Park JY. Leptin and the metabolic syndrome in Korean adolescents: factor analysis. Pediatr Int. 2004. 46:697–703.
Article
6. Oh JY, Hong YS, Sung YA, Barrett-Connor E. Prevalence and factor analysis of metabolic syndrome in an urban Korean population. Diabetes Care. 2004. 27:2027–2032.
Article
7. Choi KM, Lee J, Kim KB, Kim DR, Kim SK, Baik SH, et al. South-west Seoul Study: Factor analysis of the metabolic syndrome among elderly Koreans-the South-west Seoul Study. Diabet Med. 2003. 20:99–104.
Article
8. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes. 1997. 46:1594–1600.
Article
9. Reaven GM. The Metabolic Syndrome: Requiescat in Pace. Clinical Chemistry. 2005. 51:931–938.
Article
10. Tai ES, Goh SY, Lee JJ, Wong MS, Hang D, Hughes K, et al. Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care. 2004. 27:1728–1734.
11. Grundy SM. The Metabolic Syndrome Still Lives. Clinical Chemistry. 2005. 51:1352–1357.
12. Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ. Do Different Dimensions of the Metabolic Syndrome Change Together Over Time? Evidence supporting obesity as the central feature. Diabetes Care. 2001. 24:1758–1763.
Article
13. Everson SA, Goldberg DE, Helmrich SP, Lakka TA, Lynch JW, Salonen JT, et al. Weight gain and the risk of developing insulin resistance syndrome. Diabetes Care. 1998. 21:1637–1643.
Article
14. Stone NJ, Saxon D. Approach to Treatment of the Patient with Metabolic Syndrome: Lifestyle Therapy. Am J Cardiol. 2005. 96(4A):15E–21E.
Article
15. Bestermann W, Houston MC, Basile J, Egan B, Ferrario CM, Moore MA, et al. Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome. Am J Med Sci. 2005. 329:292–305.
Article
16. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects(XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004. 27:155–161.
17. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older. Diabetes. 2003. 52:1210–1214.
Article
18. UK Prospective Diabetes Study(UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34). Lancet. 1998. 352:854–865.
19. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care. 2000. 23:1619–1629.
20. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Taton J, et al. PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005. 366:1279–1289.
Article
21. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J. The DREAM Trial Investigators: Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia. 2004. 47:1519–1527.
Article